Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — Investor Presentation (June 2021)
24 slides from Hikma Pharmaceuticals's investor presentation, June 2021
Slide 1: Better health. Within reach. Every day.
Better health. Within reach. Every day. Meet the Management Series - Branded June 2021
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Agenda and speakers
Agenda and speakers 2:00 – 2:05pm Welcome Siggi Olafsson 2:05 – 2:15pm Branded overview Mazen Darwazah Siggi Olafsson Mazen Darwazah Commercial, CEO President of MENA & 2:15 – 2:20pm Masoud Abdelmajid products & partnership Executive Vice Chairman Manufacturing, 2:20 – 2:25pm Ma’moon Araidah R&D & p
Slide 4: Branded – A leader in the MENA region
Branded – A leader in the MENA region Injectables Generics Branded 2020 revenue 42% 32% 26% 2020 core operating profit contribution1 57% 24% 19% 1 Core operating profit is $566 million. Before unallocated corporate costs of $98 million and operating profit from Other business of zero, core operating
Slide 5: Branded
Branded Mazen Darwazah President of Branded
Slide 6: Long-term presence in the MENA region
Long-term presence in the MENA region 1978 Hikma founded in Jordan in 1978 to supply Middle East Market Expanded partnership with Takeda for key TAs 1982 Established long-term partnership with Astellas Increased Tunisia presence through IAB stake Introduced tiering of our markets 1993 Acquired Al Da
Slide 7: Leading company in the region
Leading company in the region MENA top-10 pharmaceutical companies by sales1 Selected MENA markets by size2 Tier 2 Iraq Saudi Top-10 Arabia UAE companies represent Lebanon 34% Tier 1 $31 billion Jordan of the market Morocco Tier 3 market Sudan Egypt Tunisia Others Algeria Tier 4 1 IQVIA local Pharma
Slide 8: Our Branded business today
Our Branded business today Revenue grew at CAGR of 5.3% and core EBIT at 12.7% 2016-2020 at constant currency Branded Fifth largest pharmaceutical company in MENA 23 manufacturing sites 2020 revenue 26% across the region 18 markets 5,700 employees, including over 2020 core operating 2,000 in sales a
Slide 9: A focused approach to our markets through tiering
A focused approach to our markets through tiering 2020 Branded revenue by tier Market prioritisation Syria Tunisia Morocco Lebanon Iraq Tier 3 Jordan Tier 2 20% Algeria Kuwait 15% Libya Egypt Saudi Bahrain Qatar UAE Arabia Tier 4 6% Oman Sudan Tier 1 Yemen 58% 44% of the total population of the 18 M
Slide 10: Tier 1 markets
Tier 1 markets Egypt1 Algeria1 Saudi Arabia1 6.9% 3.4% 3.1% 2.9% 4.3% 4.5% 3.6% 5.4% 3.5% 2.7% 2.4% 4.8% 3.3% 3.5% 2.7% 2.7% 5.4% 4.6% 5.0% 15.0% 8.9% 2.9% 8.1% 5.7% 5.3% 4.4% 6.6% 4.6% 8.2% 6.2% • Total market size of $4.9 billion • Total market size of $3.3 billion • Total market size of $4.6 bill
Slide 11: Branded strategy and opportunity
Branded strategy and opportunity Strategy Opportunity Continued expansion of our Tier 1 markets and Tiering the markets development of our Tier 2 and 3 markets Focus R&D and partnership opportunities on high Focus on key therapeutic areas value TAs, such as CNS, cardiovascular and diabetes Expand ex
Slide 12: Historic growth
Historic growth Branded financial performance in constant currency1 Branded financial performance as reported Core revenue Core revenue Core operating profit Core operating profit Since 2018 when we tiered our markets: Core revenue has grown at a CAGR of 6% both reported and constant currency. Core
Slide 13: Commercial, products and partnerships
Commercial, products and partnerships Masoud Abdelmajid
Slide 14: Commercial capabilities
Commercial capabilities Sales teams Tailored engagement approach Case study: Egypt Digital outreach 540+ market representatives Increasing our reach and know-how Advisory Patient in the region boards awareness Virtual conferences – hosted 140 virtual conferences since 2,000 Engaging start of 2020 re
Slide 15: Our product focus
Our product focus Building on our strong performing established products with new complex and differentiated launches Branded Generics In-licence Recently Reagila® Vipidia® launched Sclera® Divinus® Anti-psychotic Diabetes products Dimethyl Fumarate Dapagliflozin Bufomix Easyhaler® CNS Diabetes Resp
Slide 16: Importance of partnership
Importance of partnership Branded revenue split by product type Branded generics 63% In-licenced products 37% 53 partners in MENA Selected partnerships: Hikma Pharmaceuticals PLC 16
Slide 17: Manufacturing, R&D and pipeline
Manufacturing, R&D and pipeline Ma’moon Araidah
Slide 18: Extensive manufacturing capabilities
Extensive manufacturing capabilities Tunisia Morocco General formulation Cephalosporins Jordan Penicillin Oncology Egypt API Algeria Saudi Arabia 23 Manufacturing plants Sudan across the MENA region Highlights Jordan manufacturing breadth Egypt manufacturing differentiation Saudi Arabia manufacturin
Slide 19: Manufacturing in Algeria
Manufacturing in Algeria Four facilities in Algeria • General formulation • Cephalosporin • Oncology • Penicillin Dar Hikma Arabia Algeria Algeria Oncology Plant • First oral oncology plant in Algeria • 10 products registered • Additional 6 products to be registered in H2 2021 • Extension of submiss
Slide 20: Therapeutic area focus – differentiated pipeline
Therapeutic area focus – differentiated pipeline Branded pipeline of 216 projects for 57 molecules1 Pipeline by market1 Submission Morocco 20% 99 projects, 24 molecules 27% Algeria KSA 19% 99 16% Egypt Jordan 18% Development 117 projects, 33 molecules Pipeline by key therapeutic area1 19% CNS Diabet
Slide 21: Algeria pipeline
Algeria pipeline Algeria pipeline by therapeutic area Rich diversified pipeline Focus on specialty areas such as hypertension and diabetes 21% CNS Diabetes 5% Existing line extensions 12% Cardiovascular In order to maximise revenues from legacy 58 top-selling products 3% Autoimmune Projects Oral onc
Slide 22: Wrap-up
Wrap-up Mazen Darwazah
Slide 23: Summary slide
Summary slide Our Strategy: Our priorities: Tiered markets Efficiency in operations • Continue to invest in Tier 1 markets to drive • Invest in capacity and expand Mid-single digit quality growth capabilities in core markets Revenue constant currency • Focus on Tier 2 and certain Tier 3 markets • Fo
Slide 24: Branded Meet the Management - Q&A
Better health. Within reach. Every day. Branded Meet the Management - Q&A
Hikma Pharmaceuticals — Investor Presentation (June 2021) on 6ix